Cite

HARVARD Citation

    Parghane, R. et al. (2020). Clinical utility of 177Lu‐DOTATATE PRRT in somatostatin receptor‐positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. Head & neck. 42 (3), pp. 401-416. [Online]. 
  
Back to record